BioSpace News Archive

Immuno-Oncology experts PD Dr. Jessica Hassel (National Center for Tumor Diseases, Heidelberg, Germany) and Dr. Aurélien Marabelle (Gustave Roussy, Paris, France)

ArTara Therapeuticss, a clinical-stage company developing treatments for rare diseases with significant unmet needs, today announced that it has successfully completed an End-of-Phase 2 meeting with the Food and Drug Administration (FDA) to discuss study of Intravenous (IV) Choline Chloride substrate replacement for patients with Intestinal Failure Associated Liver Disease (IFALD).

Dr. Gary J.L. Foster and Eye Center of Northern Colorado is participating in the AcuFocus clinical study for the IC-8 intraocular lens (IOL) designed for patients with cataracts.

Propanc Biopharma (OTCQB: PPCB) (“Propanc”), a clinical stage biopharmaceutical company focused on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that Propanc has selected LaVoieHealthScience (“LHS”) as its communications agency of record.

Tria age-defying laser is a FDA-cleared laser for homecare use.

Three distinct datasets were used in the manuscript to validate the EDGE platform as a robust machine-learning tool for neoantigen identification.

RAMP™ is Fusion’s new proprietary service, designed to improve the affinity of therapeutic antibodies being developed by drug discovery companies.

Guided Therapeutics, Inc. (PINK SHEETS: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced that it has signed a limited Manufacturing, Supply and Royalty Agreement with its Central/Eastern European/Russian distribution partner Newmars Technologies, Inc.

Gallagher’s 2018 Benefits Strategy & Benchmarking Survey – Canada Edition shows how more than 450 employers are leveraging benefit offerings to attract and retain talent

Hope TMS Center, one of the premier mental health facilities in the Dallas-Fort Worth area, announced today that it is now treating Obsessive-Compulsive Disorder (OCD) with BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS), following its recent FDA clearance.